课题组在对药用昆虫美洲大蠊的前期研究中，获得了抗肺纤维化（IPF）作用很强的活性部位ML-D-Ⅲ，但其活性物质基础和作用机制尚未完全清楚，课题将进一步对其进行系统研究，研究内容包括：（1）在体内外活性追踪下，采用凝胶过滤色谱、制备HPLC、电泳等技术系统分离活性部位ML-D-Ⅲ中的化合物，并采用四大波谱、多肽N端氨基酸测序及多种联用技术确定化合物结构；（2）采用博莱霉素诱导大鼠肺纤维化模型对活性部位和单体化合物进行抗IPF药效评价，探讨抗IPF活性是由单一成分产生还是由多成分协同作用产生；（3）采用MTT法研究ML-D-Ⅲ和各化合物对TGF-β1刺激诱导人胚肺成纤维细胞(MRC-5)复制周期相关因子的抑制作用，以阐明其抗IPF的作用机制。 美洲大蠊系列药品的研发是云南省重点培育的五大系列"云药"特色产品之一，研究成果将为最终研发出一种高效、低毒、资源丰富的抗IPF新药奠定基础。

The material basis for efficacy and mechanism of anti- pulmonary fibrosis（IPF） in Periplaneta Americana remains unclear, though a potent part, named ML-D-Ⅲ has been achieved in our previous research. ML-D-Ⅲ extracted from Periplaneta Americana was found capable of significantly inhibiting pulmonary fibrosis replication with relatively low cytotoxicity. In this proposed research, we will do further systematic research on ML-D-Ⅲ. (1) the compounds are separated from active site ML-D-Ⅲ by Gel Chromatography, HPLC, Electrophoresis etc, and identified by IR,NMR, MS, polypeptide N-terminal amino acid sequencing etc, and tested in vitro and in vivo anti-pulmonary fibrosis properties. (2) The study objectives are to evaluate the efficacy of the active site of a single and component effect and explore the activity being governed by a single component or components produced by synergy by using Bleomycin-induced rat model of pulmonary. (3) MTT was used to study the inhibitory effect on the replication cycle factors of MRC-5 cell stimulated by TGF-β1, with the attempts to make clear the mechanism of anti-IPF of ML-D-Ⅲ and various compounds in ML-D-Ⅲ. Yunnan provincial government has listed the research and development of its relevant drugs as one of the five series of "Yun medicine" cultivated in Yunnan Province. The results will lay an important scientific foundation for the development of high efficacy, low toxicity, rich resource in anti- IPF.